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induced platelet inhibition ratio<30% (1.2% vs 8.2%, P<0.05). There
were signiﬁcant differences between clopidogrel group and ticagrelor
group in the percentages of patients with ADP-induced platelet inhi-
bition ratio <50% (29.4% vs 10.6%, P<0.05). There were also signiﬁ-
cant differences between clopidogrel group and ticagrelor group in
the percentages of patients with ADP-induced platelet inhibition
ratio>75% (41.8% vs 69.4%, P<0.05).
CONCLUSIONS ① Ticagrelor had greater inhibitory effect on the pa-
tients with ACS after PCI than Clopidogrel. ② Higher residual platelet
activity (HRPA) phenomenon also can be seen in the ticagrelor treatment
patients, although that is evenmore in clopidogrel treatment patients.
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A Meta-analysis of Randomized Clinical Trials of Dual Antiplatelet Therapy
in Patients with Drug-Eluting Stent Implantation
Jianbing ZHU, Junbo Ge
Shanghai Institute of Cardiovascular Diseases, Department of
Cardiology, Zhongshan Hospital, Fudan University, 180 Feng Lin Road,
Shanghai, China
OBJECTIVES The purpose of this study was to perform a meta-anal-
ysis comparing short-term versus long-term dual antiplatelet therapy
(DAPT) to identify the optimal duration of DAPT in patients with Drug-
Eluting Stent (DES) implantation.
METHODS This study included 15,870 patients from 7 randomized
clinical trials (RCT) comparing short-term DATP (S-DAPT) versus long-
term DATP (L-DAPT) following drug-eluting stents. We examined the
odds ratio (OR) and 95% conﬁdence intervals (Cls) of clinically sig-
niﬁcant bleeding (CSB) and stent thrombosis as primary endpoints.
Myocardial infarction, stroke, cardiovascular mortality and all-cause
mortality were evaluated as secondary endpoints.
RESULTS Compared with L-DAPT, S-DAPT had a decreased risk of CSB
(OR: 0.57 [95% CI: 0.40 to 0.81]; p < 0.01). The rates of stent throm-
bosis (OR: 1.20 [95% CI: 0.77 to 1.88]; p > 0.05), myocardial infarction
(OR: 1.13 [95% CI: 0.88 to 1.44]; p > 0.05), stroke (OR: 0.88 [95% CI:
0.57 to 1.36]; p > 0.05), cardiovascular mortality (OR: 0.99 [95% CI:
0.72 to 1.36]; p > 0.05) and all-cause mortality (OR: 0.93 [95% CI: 0.74
to 1.18]; p > 0.05) were similar.
CONCLUSIONS S-DAPT for treatment in patients with DES implanta-
tion is associated with a signiﬁcant reduction of CSB compared with
L-DAPT.
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The lowering lipid efﬁcacy of low-dose simvastatin and ezetimibe
compared to high-dose simvastatin alone: A meta-analysis
Ning Zhang, Qizhu Tang
Renmin Hospital of Wuhan University, Wuhan 430060, China
OBJECTIVES The ezetimibe/simvastatin combination tablet and high-
dose simvastatin monotherapy represent two major options for treat-
ment of patients with hyercholesterolemia. The lowering lipid effect of
direct comparative studies between ezetimibe/simvastatin (10/10mg)
and high-dose simvastatin(40mg or 80mg) therapies have not been
reported. To evaluate whether low-dose simvastatin/ezetimibe 10/
10mg would achieve the same lowering lipid efﬁcacy compared to
simvastatin 40mg or 80mg in treatment of patients with dyslipidemia.
METHODS Randomized controlled trials (RCTs) regarding to the pa-
tients with dyslipidemia in treatment of ezetimibe and simvastatin
were retrieved in PubMed, EMBASE and Cochrane Central Register of
Controlled Trials (CENTRAL). We also searched the reference lists of
relevant papers. Data was extracted by two reviewers independently.
Statistical analysis was performed using RevMan 5.2.
RESULTS 8 RCTs including 202 high-dose simvastatin controls and
200 low-dose simvastatin / ezetimibe patients were enrolled in our
meta-analysis. Low density lipoprotein - cholesterol (MD, -0.27; 95%
CI, -3.82 to 3.28; P ¼0.88), high density lipoprotein-cholesterol
(MD, 0.32; 95%CI, -1.32 to 1.95; P ¼0.88), the total cholesterol
level (MD, 0.76; 95%CI, -4.14 to 5.65; P ¼0.76), Apolipoprotein B (MD,
-1.70; 95 %CI, -7.10 to 3.71; P ¼0.54) and apolipoprotein A-I level (MD,
-2.75; 95%CI, -9.72 to 4.23; P ¼0.44) were at the same level after the
low-dose ezetimibe / simvastatin 10/10mg and simvastatin 40mg or 80
mg treatment respectively. However, the maximal dose of simvastatin
can reduce the teriglyrides effectively compared to low-dose simva-
statin/ezetimibe (MD, 14.35; 95%CI, 9.51 to 19.20; P <0.00001).
CONCLUSIONS Our study demonstrate ezetimibe/simvastatin
10/10mg can reach the same lowering lipid parameters such as LDL-C,total cholesterol, Apoliprotein B compared to the maximal-dose sim-
vastin 40mg or 80 mg. These results suggest that ezetimibe/simva-
statin 10/10mg is comparable to the high-dose simvastatin 40mg or
80mg, however, the maximal dose of simvastatin can reduce the tri-
glycerides effectively compared to low-dose simvastatin/ezetimibe.
Two agents can reduce ApoB level and increase the anti-atheroscle-
rosis lipidprotein ApoA-I, and two treatment strategies have same
favorable effect on lipoprotein proﬁles.
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Effectiveness and safety of tolvaptan in chinese heart failure patients with
reduced left ventricular systolic function
Lijin Zeng, Zhibin Chen, Jingguo Wu, Wen Yang, Zhenyu Li
First Afﬁliated Hospital of Sun Yet-sen University
OBJECTIVES To examine the efﬁcacy and safety of tolvaptan in acute
decompensated heart failure patients with reduced left ventricular
systolic function.
METHODS A total of 145 hospitalized acute decompensated heart
failure patients were randomly assigned to either a tolvaptan(n¼79) or
a control group(n¼66) which used conventional treatment only.
Baseline clinical characteristics were not different between the two
groups. We divided these patients based on the left ventricular ejec-
tion fraction (EF) by echocardiography.
RESULTS There was no signiﬁcant difference of daily urine volume
between the tolvaptan and control groups in patients with preserved
EF ( 50%).The urine volume was signiﬁcantly higher in the tolvaptan
group than in the control group in those with reduced EF (< 50%)(P <
0.05 ).In the safety proﬁle, the incidence rate of thirst was higher in
the tolvaptan group than that in control group (21.5% versus 7.6%,
P<0.05). The incidence of hypernatremia( 150 mEq/L) in tolvaptan
group was no signiﬁcant difference than that in control group (6.3%
versus 3.0%, P>0.05).
CONCLUSIONS This study reveals that tolvaptan is more effec-
tive than conventional treatment in acute decompensated heart failure
patients with reduced left ventricular systolic function and it is safety.
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Effects of Shensongyangxin capsule on heart rates variability and insomnia
in maintenance hemodialysis patients
Zhenda Zheng, Caihong Qu, Xiaoju Ma, Jianrui Zheng, Cailian Cheng
the Third Afﬁliated Hospital of Sum Yat-sen University, Guangzhou
OBJECTIVES To investigate the efﬁcacy and safety of Shenson-
gyangxin capsule (SSYX) on heart rate variability (HRV) and insomnia
in maintenance hemodialysis patients.
METHODS sixty-three maintenance hemodialysis patients in the third
afﬁliated hospital of Sun Yat-Sen University from 2013 June to
December were divided into two groups, SSYX treatment group(n¼33)
and control group(n¼30). SSYX treatment group were received SSYX 4
capsules four times a day for eight weeks, all patients received 24-h-
holter test and Pittsburgh sleep quality index were measured at both
baseline and eight weeks in these sixty-three patients.
RESULTS SSYX can improve heart rate variability [SDNN (93.21.4)
vs.(82.413.1) ms, SDNNi (41.212.8) vs. (28.412.2)ms, SDANNi
(81.321.1) vs. (73.220.7)ms, RMSSD (28.313.2)vs.(21.811.9)ms,
PNN50 (9.67.1) vs.(7.15.8)%, P<0.05], SSYX can decrease the inci-
dence of arrhythmia [premature atrial contraction(60.6% vs.24.2%),
atrial tachycardia (45.5% vs.12.1%), premature ventricular contrac-
tion(9.1% vs.3%), ventricular tachycardia(21.2% vs.9.1%), atrial-ven-
tricular blocker (60.6% vs.24.2%), P<0.05], SSYX also improved sleep
quality signiﬁcantly[PSQI (6.282.12) vs.( 14.392.84), P<0.05]. There
was no severe adverse events registered during the study.
CONCLUSIONS Clinical use of SSYX was safe and effective for treating
hemodialysis patients with decrease HRV and insomnia.
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Effects of dabigatran on coagulation assays in aged patients with atrial
ﬁbrillation : Two cases report
Xiaoping Hou, Xuan Wei, Yanyan Li
Air Force General Hospital of PLA
OBJECTIVES To report the effects of dabigatran etexilate on routine
coagulation assays in two aged patients with atrial ﬁbrillation.
METHODS The data of routine coagulation assays from two aged cases
treated with dabigatran etexilate were retrospectively reviewed,
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(aPTT), prothrombin time (PT), international normalized ratio (INR),
and ﬁbrinogen (FIB).
RESULTS Two patients, one was a 78-year-old female, another a 71-
year-old male, took oral dabigatran etexilate 110mg bid or 150mg bid
for stroke prevention. The remarkable prolongation of TT and mild
prolongation of aPTT were detected during treatment, while the INR
and FIB were normal. The longest TT was 147 seconds (upper limit of
normal 21 seconds).The extended TT and aPTT returned to normal
three or ﬁve days after dabigatran etexilate discontinued. The female
one received dabigatran etexilate again, and Then, TT, aPTT pro-
longed again. The patient also occurred subcutaneous hemorrhage.
After dabigatran etexilate was reduced to 55 mg qd, TT prolongation
was shorten and aPTT became to normal.
CONCLUSIONS Oral dabigatran etexilate can cause remarkable pro-
longation of TT and mild prolongation of aPTT. It is suggested that TT
and aPTT could be used for monitoring and evaluating the anticoag-
ulant effects of dabigatran etexilate.
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The effect of long-term application of small doses atorvastatin in elderly
patients with hyperlipidemia on serum uric acid
Huijuan He, Jun Jin, Shufeng Xue, Jianfeng Chen, Yunfei Gu,
Shouyan Zhang
Luoyang Central Hospital Afﬁliated To Zhengzhou University
OBJECTIVES To explore the effect of long-term application of small
doses atorvastatin in elderly patients with hyperlipidemia on serum
uric acid (UA).
METHODS 220 elderly patients with hyperlipidemia June 2008 -
October 2012 were randomly divided into 10mg/d atorvastatin group
and 20 mg/d simvastatin group. Blood uric acid and lipid before and
after treatment were observed.
RESULTS Serum total cholesterol (TC), lowdensity lipoprotein cholesterol
(LDL-C) and triglyceride (TG) levels were signiﬁcantly decreased, high-
density lipoprotein cholesterol (HDL-C) increased in both groups after 12
months treatment. Blood uric acid levels were signiﬁcantly decreased,
and high-density lipoprotein cholesterol (HDL-C)increased in atorvastatin
group compared to simvastatin group.
CONCLUSIONS Atorvastatin can effectively reduce elderly patients with
hyperlipidemia lipid levels, also had reduced the level of UA. Atorvastatin
reducedthelevelofUAindependentof thelipid-loweringeffect,whichcould
play a certain role in reducing the incidence of cardiovascular events.CARDIAC REHABILITATIONREHABILITATION FUNCTIONAL ASSESSMENT
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The Association Between Pre-operative Physical Performance and Length
of Stay in Hospital after Coronary Artery Bypass Graft Surgery
Wen Zhang,1 Guo Qi1,2
1Department of Rehabilitation and Sports Medicine, Tianjin Medical
University, Tianjin, China; 2Department of Rehabilitation Medicine,
Cardiovascular Clinical College of Tianjin Medical University, TEDA
International Cardiovascular Hospital, Tian
OBJECTIVES To determine whether patient pre-operative physical
performance was associated with length of stay in hospital after
coronary artery bypass graft surgery (CABG).
METHODS Our study population comprised 50 subjects (mean  SD
age: 63.0  7.3 years; 62% men) who were undergoing CABG. All pa-
tients were assessed for several simple physical parameters, including
muscle strength (hand grip strength test), balance (functional reach
test), mobility (4-meter walk test) and functional capacity (6-minute
walk test) before surgery.
RESULTS In multivariate analysis, after adjusting for sex, age, body
mass index, severity of coronary heart disease, history of other dis-
eases, daily living activity, smoking and drinking status, psychological
conditions and surgery situations, we found that decreasedperformance in the muscle strength test (grip OR 11.08, 95%CI 1.39-
18.69), balance test (functional reach test OR 9.43, 95% CI 1.04-25.95),
mobility test (4-meter walk test OR 9.53, 95%CI 1.37-16.38) and
functional capacity test (6-minute walk test OR 15.49, 95%CI 1.18-
34.09) were independently associated with longer hospital stays after
CABG.
CONCLUSIONS We conclude that pre-operative performance-based
physical assessments may be useful predictors of outcomes in
patients undergoing CABG.MEDICAL REHABILITATION OF
CARDIOVASCULAR DISEASE
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The diversity of BMI and WC on cardiac damage in patients from a cardiac
rehabilitation program after acute coronary syndrome
Lin Xu, Hui Zhao, Jun Ma, Wei Zhu, Hongqiang Lei, Zekun Cai,
Yongwang Fan, Xiaoming Huang, Jiangming Huang, Xinyuan Zhao,
Yu Shao, Yanzhuo Li, Jian Qiu
Guangzhou General Hospital of Guangzhou Military Region, PLA
OBJECTIVES One of the purposes of cardiac rehabilitation (CR) after
acute coronary syndrome (ACS) is to monitor and control weight of the
patient. Our study is to compare the different obesity indexes, body
mass index (BMI) and waist circumference (WC), through one well-
designed CR program (CRP) with ACS in Guangzhou city of Guangdong
Province, China, in order to identify different effects of BMI and WC
on organ damage.
METHODS In our work, sixty-one patients between October 2013 and
January 2014 fulﬁlled our study. We collected the vital signs by
medical records, the clinical variables of body-metabolic status by
fasting blood test, and the organ damage variables by Sub-Maximal
exercise treadmill test (ETT) and Ultrasonic cardiogram (UCG) both on
our in-patient and four-to-ﬁve weeks of out-patient part of CRP after
ACS. We mainly used two-tailed Pearson’s test and liner regression to
evaluate the relationship of BMI/WC and organ damage.
RESULTS There were ﬁve key ﬁndings:
1) Obesity assessed by increasing WC was signiﬁcantly associated
with lower HDL_C, higher LVSd, and higher LVPWd in patients from a
CRP after ACS. However, the associations were insigniﬁcant when the
obesity was assessed by BMI.
2) WC had a highly linear correlation with indices that reﬂected
cardiac structure alteration while BMI not.
3) WC was the only signiﬁcant factor remaining in the model when a
multiple linear regression analysis was performed to estimate the
effects of WC and BMI on cardiac structure alteration.
4) After adjusted by age, smoking, hypertension, diabetes, TC, and
HDL_C, WC still kept in signiﬁcant correlation with cardiac structure
alteration.
5) Obesity assessed by increasing BMI was signiﬁcantly associated
with higher SBP and DBP in patients from a CRP after ACS. However,
when the obesity was assessed byWC, the associations were signiﬁcant
only for the subjects after CRP but not for the subjects before CRP.
CONCLUSIONS Our results conﬁrmed that WC could be more accurate
than BMI to evaluate the cardiac function through the changes of left
ventricular structure on the CRP after ACS cases. It makes sense of
early diagnosis, valid evaluation and proper adjustment to ACS in CRP
of the obesity individuals in the future.
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Relationship between catestatin and heart rate recovery after acute
myocardial infarction
Yane Liu, Wei Zhao, Wei Gao
Department of Cardiology, Peking University Third Hospital
OBJECTIVES To investigate the relationship between catestatin level
and heart rate recovery in patients with acute myocardial infarction
treated with direct emergency PCI.
METHODS The population of our study comprised 80 consecutive
patients with STEMI who were admitted to the ward of cardiology
department in Peking University Third Hospital from October 2011 to
March 2013. The levels of plasma catestain and norepinephrine (NE)
were detected by ELISA. All the patients were conducted cardiopul-
monary exercise testing (CPET) evaluation within 45 days after acute
myocardial infarction, and heart rate recovery at 1min and 2 min after
CPET (HRR1, HRR2) were calculated. Data analysis were performed
with SPSS 20.0.
